B-type natriuretic peptide for diagnosis and therapy

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 2, 2008, Pages 77-83

  Jankowski, Marek ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atrial natriuretic peptide; BNP 32; Diagnosis; Heart failure; Human brain natriuretic peptide; NT proBNP; Prognosis; Treatment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NESIRITIDE; REAGENT; RECOMBINANT BRAIN NATRIURETIC PEPTIDE; RECOMBINANT HORMONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); RECOMBINANT PROTEIN;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOMEOSTASIS; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOASSAY; INSOMNIA; LOW DRUG DOSE; NAUSEA; NONHUMAN; PATENT; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; AMINO ACID SEQUENCE; ANALYTICAL EQUIPMENT; BLOOD; HEART DISEASE; HOSPITAL INFORMATION SYSTEM; MOLECULAR GENETICS; REVIEW; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; HEART DISEASES; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, BRAIN; PATENTS AS TOPIC; PEPTIDE FRAGMENTS; POINT-OF-CARE SYSTEMS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 51149114873     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008784705395     Document Type: Article

References (84)

1. De Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94.
2. Goetz K, Drummer C, Zhu JL, et al. Evidence that urodilatin, rather than ANP, regulates renal sodium excretion. J Am Soc Nephr 1990; 1:867-874.
3. Sudoh T, Kangawa K, Minamino M, et al. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
4. Cataliotti A, Chen HH, James KD, et al. Oral brain natriuretic peptide: A novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med 2007; 17:10-14.
5. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans - Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412.
6. Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168:863-870.
7. Tervonen V, Arjamaa O, Kokkonen K, et al. A novel cardiac hormone related to A-, B- and C-type natriuretic peptides. Endocrinology. 1998; 139:4021-4025.
8. Singh G, Kuc RE, Maguire JJ, et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: Downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006; 99:183-190.
9. Lee CYW, Burnett JC Jr. Nariuretic peptides and therapeutic applications. Heart Fail Rev 2007; 12:131-142.
10. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-1088.
11. De Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31:7-18.
12. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6:257-260.
13. Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993; 76:832-838.
14. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007; 49:1114-1119.
15. Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006; 52:1054-1061.
16. Shimizu H, Aono K, Masuta K, et al. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999; 285:169-172.
17. van der Merwe DE, Henley R, Lane G, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. Clin Chem 2004; 50:779-780.
18. Belenky, A., Livshin, L.A., Barbarakis, M.: WO06102612 (2006).
19. Shimizu, H., Asada, H., Endo, K.: WO022235 (1999).
20. Shih, J. W., Pinkus, M. S., Tyner, J. D., Brophy, S. E., Tu, Bailin.: WO07056507 (2007).
21. Shih, J. W., Tyner, J. D., Matias M.S., Pinkus, M. S., Brophy, S. E., Daghfal D.J., Hawksworth, D.J.: WO06088700 (2006).
22. Mischak, R. P., Lim, G. A., Scardina, J. M.: WO032900 (1997).
23. Asada, H., Shimizu, H., Endou, K.: WO013331 (1999).
24. Campbell, J.E.L., Frank, P.A., Hawkes, M.E., Lobin, S.R., Miller, C.J.; Yang, Z.: WO04011947 (2004).
25. Kono, M., Tsuji, T., Inouye, K., Yamauchi, A., Igano, K.: US20046677124 (2004).
26. Dzieglewska, H., Medinnova E, Hall, C.: WO024531 (1993).
27. Klemt, V., Borgya, A., Gallusser, A.,Grol, M., Hallermayer, K., Seidel, C.: WO04099253 (2004).
28. Borgya, A., Gallusser, A., Grol, M., Hallermayer, K., Klemt, V., Seidel, C.: US20077264939 (2007).
29. Borgya, A., Gallusser, A., Grol, M., Hallermayer, K., Klemt, V., Seidel, C.: US20077264938 (2007).
30. Borgya, A., Gallusser, A., Grol, M., Hallermayer, K., Klemt, V., Seidel, C.: US20070117156 (2007).
31. DeBold, A.: US20056960472 (2005).
32. Hess, G., Horsch, A.: WO06131529 (2006).
33. Vuolteenaho, O., Ala-Kopsala, M., Ruskoaho, H., Leppäluoto, J. Haapalahti.: WO05003764 (2005).
34. Hess, G., Horsch, A.: WO05124364 (2005).
35. Ng, L.: WO04034903 (2004).
36. Minamino, T., Hori, M., Okada, K., Kitakaze, M.: US20070065850 (2007).
37. Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure. Circulation 2007; 116: 249-257.
38. Matsumori, A.: WO07023815 (2007).
39. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med 2002; 347:161-167.
40. Mogelvang R, Goetze JP, Schnohr P, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-b-type natriuretic peptide. J Am Coll Cardiol 2007; 50:1694-1701.
41. Mueller C. B-type natriuretic peptides and the general practitioner. J Am Coll Cardiol 2007; 50:1702-1703.
42. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: Is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001; 101:621-628.
43. deFilippi CR, Seliger SL, Maynard S, et al. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53:1511-1519.
44. Winter WE, Elin RJ. The role and assessment of ventricular peptides in heart failure. Clin Lab Med 2004; 24: 235-274.
45. Iwanaga Y, Kihara Y, Niizuma S, et al. BNP in overweight and obese patients with heart failure: An analysis based on the bnp-1v diastolic wall stress relationship. J Card Fail 2007; 13: 663-667.
46. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure. A pro-BNP investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J 2005; 149:744-750.
47. Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: Insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 2006; 48:1808-1812.
48. Protter, A.A.: WO07041645 (2007).
49. Amann-Zalan, I., Trauth, B., Rivera, O.J.M.: WO06120152 (2006).
50. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
51. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007; 28:1678-1682.
52. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006; 47: 874-880.
53. Masson S, Latini R, Anad IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The valsartan heart failure (Val-HeFT) data. Clin Chem. 2006;106: 416-422.
54. Uusimaa P, Ruskoaho H, Vuolteenaho O, et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 1999; 69:5-14.
55. McCullough PA, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106:416-422.
56. Klemt, V., Borgya, A., Gallusser, A., Grol, M., Hallermayer, K., Seidel, C.: WO04099253 (2004).
57. Klemt, V., Borgya, A., Gallusser, A., Grol, M., Hallermayer, K., Seidel.: WO04099252 (2004).
58. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.
59. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: A community-based study. Circulation 2004; 109: 3176-3181.
60. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353.
61. Yeo K-T, Lee H-K, Wong K-C, et al. Can exercise-induced changes in B-type natriuretic peptides be used to detect cardiac ischemia? J Card Fail 2005; 11: S59-S64.
62. Zoghbi, W. A., Win, H. K.: WO04082639 (2004).
63. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005; 294: 2866-2871.
64. Ndrepepa G, Braun S, Schömig A, et al. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. Am J Cardiol 2007; 100: 575-578.
65. Dahlen, J.R., Valkirs, G.E., Buechler, K. F.: WO02083913 (2002).
66. Diamond. C., Man, A., Bremer, T.: US20050181386 (2005).
67. Conen D, Pfisterer M, Martina B. Substantial intraindividual variability of BNP concentrations in patients with hypertension. J Hum Hypert 2006; 20: 387-391.
68. Spanuth, E.: WO06077265 (2006).
69. DeBold, A.: US20006117644 (2000).
70. Spanuth, E.: WO07104682 (2007).
71. Seilhamer, J.J., Lewicki J., Scarborough, R.M., Porter, J.G.: US5674710 (1997).
72. Schreiner, G. F.: WO03081246 (2003).
73. Seilhamer, J. J., Lewicki, J., Scarborough, R. M., Porter, G. J.: US20060030004 (2006).
74. James, K.: WO06076471 (2006).
75. Lambeir, A-M., Brandt, I., Scharpé, S., De Meester, I.: WO06108686 (2006).
76. Huang, M., Uretsky, B.: WO07033211 (2007).
77. Pollitt, S. N., Buckley, D. I., Stathis, P. A., Hartman T. E., Zhong, Z.: US 5114923 (1992).
78. Masafumi K.: US20067026293 (2006).
79. Sackner-Bernstein JD, Kowalski M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005; 293:1900-1905.
80. Iglesias JI, Depalma L, Hom D, et al. Predictors of mortality in adult patients with congestive heart failure receiving nesiritide retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction. Nephrol Dial Transplant 2008; 23:144-153.
81. Feldman DS, Sun B. Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting. Heart Fail Rev 2004; 9:203-208.
82. Chen HH, Sundt DJ, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: A double-blind placebo-controlled pilot study. Circulation 2007; 116: I-133- I-138.
83. Simari, R.D.: US20060025367 (2006).
84. Burnett, J.Jr., Lisy, O.: US2005059600 (2005).